The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions.If you have any queries about the SPCs on our website then please e-mail

CANIXIN DHPPi/L lyophilisate suspension for injection for dogs

Virbac S.A.VPA10988/101/002

Main Information

Trade NameCANIXIN DHPPi/L lyophilisate suspension for injection for dogs
Active SubstancesCanine distemper virus
Canine adenovirus type 2
Canine parvovirus
Canine parainfluenza
L. icterohaemorrhagiae
Dosage FormLyophilisate and suspension for suspension for injection
Licence HolderVirbac S.A.
Licence NumberVPA10988/101/002

Group Information

ATC CodeQI07AI02 live canine distemper virus + live canine adenovirus + live canine parainfluenza virus + live canine parvovirus + inactivated leptospira
Therapeutic ClassImmunological - Live Vaccine


License statusAuthorised
Licence Issued11/12/2015
Legal StatusPOM: Prescription Only Medicine as defined in relevant national legislation


Summary of Product Characteristics *PDF Version
Package LeafletNo document available
Public Assessment ReportNo document available
VariationsNo document available

* The PDF document, together with the national-specific product information on this page, constitute the authorised SPC
« Back